Replies to post #87188 on Ayala Pharmaceuticals Inc (ADXS)

[Zoltarak]

In all fairness, it's very easy to play "armchair QB" when hindsight is 20/20. I won't presume to know, since I do not have all the data around me.

In short, could Advaxis LT have prevented this decline? Maybe eased it, if they had diluted at $6 or $8, but we don't have all the information and, after all, hindsight is ALWAYS 20/20.

Best of luck.

Z

[blueyedcatch]

I agree,let`s sue them all. The whole thing stinks so bad,it`s gotta be criminal. Ken pulled the EU after we waited 2 years for it to be submitted,and just days after his hiring. Then Ken says may wind Axal Cervix,as he`s shopping a share offering for Adxs. I should`ve sold when Edelman did,which was right after Ken pulled the EU. This company intentionally killed it`s share price so they could all get cheap shares. I can`t prove it,but if it looks like a duck and quacks like one,then it is,and in Adxs`s case,it`s a duck that`s been road killed,so no one wants to eat it now.It`s so ridiculous that now Ken says 500 million a year in revenue potential for Axal Cervix alone,,while the share price is a negative of cash on hand by millions of dollars at this level. A phase 3 company with a drug that can bring in 500 million in revenue a year is worth money in the share price,no? Where is it? Ken screwed the pooch to line his pockets,and now the street has to adjust the share price to include Cervix again,,but it won`t happen now until the FDA green lights the new trial,and keeps the SPA,and then a partner for it. Then we`ll rocket up to fair value for it,,not before.I think Ken was told that the share price will be brought back up after Cervix is greenlighted and partnered,so that`s why the BOD`s not sweating this whole thing,,they planned it,and they`ll revive it soon,but they should be sued for this.

[hovacre]

Where the f*k is AMGN $500M deal money????

Ken dropped a hint here, that the milestones are downstream in the clinical development of NEO. At this point, given the lack of a milestone payment upon initiation of the first patient, my presumption becomes that the milestone payment will come upon establishment of proof of concept, at which point they turn over development to AMGN, somewhat similar to the GERN-JNJ deal.